{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:18:53Z","timestamp":1782908333347,"version":"3.54.5"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"DOI":"10.1371\/journal.ppat.1010821","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T17:45:06Z","timestamp":1663782306000},"page":"e1010821","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Can live-attenuated SARS-CoV-2 vaccine contribute to stopping the pandemic?"],"prefix":"10.1371","volume":"18","author":[{"given":"Patrick Chun Hean","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wern Hann","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J. C.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-8410","authenticated-orcid":true,"given":"Suresh","family":"Mahalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"key":"ppat.1010821.ref001","article-title":"Development of vaccines for SARS-CoV-2","volume":"9","author":"WH Ng","year":"2020","journal-title":"F1000Res"},{"issue":"29","key":"ppat.1010821.ref002","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2102775118","article-title":"Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy","volume":"118","author":"Y Wang","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"ppat.1010821.ref003","article-title":"Cold-Adapted Live Attenuated SARS-Cov-2 Vaccine Completely Protects Human ACE2 Transgenic Mice from SARS-Cov-2 Infection","volume":"8","author":"SH Seo","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"ppat.1010821.ref004","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1038\/s41467-021-23166-0","article-title":"Characterization of an attenuated SARS-CoV-2 variant with a deletion at the S1\/S2 junction of the spike protein","volume":"12","author":"P Wang","year":"2021","journal-title":"Nat Commun"},{"key":"ppat.1010821.ref005","first-page":"479","article-title":"Live attenuated vaccines: Historical successes and current challenges","author":"PD Minor","year":"2015","journal-title":"Virology"},{"issue":"7821","key":"ppat.1010821.ref006","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"N Le Bert","year":"2020","journal-title":"Nature"},{"issue":"18","key":"ppat.1010821.ref007","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1056\/NEJMoa2026116","article-title":"Humoral Immune Response to SARS-CoV-2 in Iceland","volume":"383","author":"DF Gudbjartsson","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"ppat.1010821.ref008","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1473-3099(21)00676-9","article-title":"Protective immunity after recovery from SARS-CoV-2 infection","volume":"22","author":"N Kojima","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"ppat.1010821.ref009","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2020.11.029","article-title":"Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19","volume":"184","author":"LB Rodda","year":"2021","journal-title":"Cell"},{"issue":"11","key":"ppat.1010821.ref010","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","volume":"21","author":"Y Peng","year":"2020","journal-title":"Nat Immunol"},{"issue":"6529","key":"ppat.1010821.ref011","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"JM Dan","year":"2021","journal-title":"Science"},{"issue":"6","key":"ppat.1010821.ref012","doi-asserted-by":"crossref","first-page":"110345","DOI":"10.1016\/j.celrep.2022.110345","article-title":"Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses","volume":"38","author":"H Balachandran","year":"2022","journal-title":"Cell Rep"},{"issue":"3","key":"ppat.1010821.ref013","doi-asserted-by":"crossref","first-page":"100208","DOI":"10.1016\/j.xcrm.2021.100208","article-title":"Integrated immune dynamics define correlates of COVID-19 severity and antibody responses","volume":"2","author":"M Koutsakos","year":"2021","journal-title":"Cell Rep Med"},{"issue":"12","key":"ppat.1010821.ref014","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans","volume":"5","author":"J Seow","year":"2020","journal-title":"Nat Microbiol"},{"issue":"6556","key":"ppat.1010821.ref015","doi-asserted-by":"crossref","DOI":"10.1126\/science.abh1766","article-title":"Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants","volume":"373","author":"L Wang","year":"2021","journal-title":"Science"},{"issue":"1","key":"ppat.1010821.ref016","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1093\/cid\/ciac262","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study","volume":"75","author":"S Gazit","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"15","key":"ppat.1010821.ref017","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJMoa2108453","article-title":"Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors","volume":"385","author":"CW Tan","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"ppat.1010821.ref018","doi-asserted-by":"crossref","first-page":"e2213606","DOI":"10.1001\/jamanetworkopen.2022.13606","article-title":"Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals","volume":"5","author":"J Jung","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"ppat.1010821.ref019","doi-asserted-by":"crossref","first-page":"e1009509","DOI":"10.1371\/journal.ppat.1009509","article-title":"Individuals cannot rely on COVID-19 herd immunity: Durable immunity to viral disease is limited to viruses with obligate viremic spread","volume":"17","author":"JW Yewdell","year":"2021","journal-title":"PLoS Pathog"},{"issue":"6553","key":"ppat.1010821.ref020","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1126\/science.abg9857","article-title":"Scent of a vaccine","volume":"373","author":"FE Lund","year":"2021","journal-title":"Science"},{"issue":"24","key":"ppat.1010821.ref021","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar","volume":"385","author":"H Chemaitelly","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"ppat.1010821.ref022","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41591-021-01548-7","article-title":"Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK","volume":"27","author":"KB Pouwels","year":"2021","journal-title":"Nat Med"},{"key":"ppat.1010821.ref023","article-title":"Shedding of Infectious SARS-CoV-2 Despite Vaccination","volume":"2021","author":"KK Riemersma","year":"2021","journal-title":"medRxiv"},{"issue":"7","key":"ppat.1010821.ref024","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals","volume":"181","author":"A Grifoni","year":"2020","journal-title":"Cell"},{"issue":"2","key":"ppat.1010821.ref025","first-page":"362","article-title":"Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers","volume":"11","author":"YJ Tan","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"issue":"8","key":"ppat.1010821.ref026","doi-asserted-by":"crossref","first-page":"109164","DOI":"10.1016\/j.celrep.2021.109164","article-title":"Epitope profiling reveals binding signatures of SARS-CoV-2 immune response in natural infection and cross-reactivity with endemic human CoVs","volume":"35","author":"CI Stoddard","year":"2021","journal-title":"Cell Rep"},{"key":"ppat.1010821.ref027","doi-asserted-by":"crossref","first-page":"835830","DOI":"10.3389\/fimmu.2022.835830","article-title":"Dominant CD8(+) T Cell Nucleocapsid Targeting in SARS-CoV-2 Infection and Broad Spike Targeting From Vaccination","volume":"13","author":"E Taus","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"ppat.1010821.ref028","doi-asserted-by":"crossref","first-page":"100204","DOI":"10.1016\/j.xcrm.2021.100204","article-title":"Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases","volume":"2","author":"A Tarke","year":"2021","journal-title":"Cell Rep Med"},{"issue":"64","key":"ppat.1010821.ref029","doi-asserted-by":"crossref","first-page":"eabk0894","DOI":"10.1126\/sciimmunol.abk0894","article-title":"Identification of resident memory CD8(+) T cells with functional specificity for SARS-CoV-2 in unexposed oropharyngeal lymphoid tissue","volume":"6","author":"J Niessl","year":"2021","journal-title":"Sci Immunol"},{"issue":"4","key":"ppat.1010821.ref030","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2014.09.007","article-title":"CD4+ T cell help guides formation of CD103+ lung-resident memory CD8+ T cells during influenza viral infection","volume":"41","author":"BJ Laidlaw","year":"2014","journal-title":"Immunity"},{"issue":"4","key":"ppat.1010821.ref031","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.immuni.2021.03.005","article-title":"Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19","volume":"54","author":"PA Szabo","year":"2021","journal-title":"Immunity"},{"issue":"8","key":"ppat.1010821.ref032","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210583","article-title":"Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics","volume":"218","author":"NR Cheemarla","year":"2021","journal-title":"J Exp Med"},{"issue":"4","key":"ppat.1010821.ref033","doi-asserted-by":"crossref","first-page":"672","DOI":"10.4269\/ajtmh.1984.33.672","article-title":"Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. III. Reversion to virulence by passage of cloned virus in fetal rhesus lung cells","volume":"33","author":"SB Halstead","year":"1984","journal-title":"Am J Trop Med Hyg"},{"issue":"23\u201324","key":"ppat.1010821.ref034","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1016\/S0264-410X(01)00020-2","article-title":"Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers","volume":"19","author":"N Kanesa-thasan","year":"2001","journal-title":"Vaccine"},{"issue":"1","key":"ppat.1010821.ref035","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s40588-018-0080-3","article-title":"Attenuation of Viruses by Large-Scale Recoding of their Genomes: the Selection Is Always Biased","volume":"5","author":"N Osterrieder","year":"2018","journal-title":"Curr Clin Microbiol Rep"},{"issue":"68","key":"ppat.1010821.ref036","doi-asserted-by":"crossref","first-page":"eabn8014","DOI":"10.1126\/sciimmunol.abn8014","article-title":"Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants","volume":"7","author":"TA Bates","year":"2022","journal-title":"Sci Immunol"}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1010821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T21:04:00Z","timestamp":1676840640000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1010821"}},"subtitle":[],"editor":[{"given":"Thomas E.","family":"Morrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1010821","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,21]]}}}